Trials / Terminated
TerminatedNCT03675776
Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)
A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Naurex, Inc, an affiliate of Allergan plc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The study will evaluate the efficacy, safety, and tolerability of 225 milligrams (mg) and 450 milligrams (mg) of Rapastinel, compared to placebo in participants with major depressive disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rapastinel | Rapastinel (prefilled syringe, weekly intravenous IV administration). |
| DRUG | Placebo | Placebo (prefilled syringe, weekly IV administration). |
Timeline
- Start date
- 2018-10-30
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
- First posted
- 2018-09-18
- Last updated
- 2020-07-28
- Results posted
- 2020-07-28
Locations
23 sites across 5 countries: Hungary, Japan, Poland, Russia, Slovakia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03675776. Inclusion in this directory is not an endorsement.